COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF FIBROTIC, INFLAMMATORY, AND NEOVASCULARIZATION CONDITIONS OF THE EYE
The present invention relates to compositions and methods for prevention and treatment of ocular diseases and conditions characterized by aberrant fibrogenesis or scarring, inflammation and/or aberrant neovascularization or angiogenesis. The compositions and methods of the invention utilize immune-derived moieties that are specifically reactive against bioactive lipids and which are capable of decreasing the effective concentration of said bioactive lipid. In some embodiments, the immune-derived moiety is a monoclonal antibody that is reactive against sphingosine-1-phosphate (S1P) or lysophosphatidic acid (LPA).
1 . A method of treating a tissue of an eye of an animal, comprising administering to said animal an immune-derived moiety reactive against a bioactive lipid, wherein said immune-derived moiety is capable of decreasing the effective concentration of said bioactive lipid, to effect treatment of the eye.
2 . A method according to claim 1 , wherein said treatment:
a. decreases or prevents aberrant fibrogenesis, fibrosis, or scarring of said eye;
b. modulates surgical or traumatic wound healing responses of said eye;
c. decreases or prevents inflammation of said eye;
d. decreases or prevents aberrant neovascularization of said eye;
e. attenuates an ocular immune response; or
f. decreases the effective ocular concentration or activity of said bioactive lipid;
3 . A method according to claim 1 , wherein said immune-derived moiety is a monoclonal antibody or a fragment, variant, or a derivative thereof, optionally reactive against S1P or LPA or a variant thereof.
4 . A method according to claim 1 , wherein said bioactive lipid is a lysolipid, optionally S1P or LPA or a variant thereof.
5 . A method according to claim 1 , wherein the animal is a human.
6 . A method of treating an ocular disease or condition in a subject, comprising administering to said subject a pharmaceutical composition comprising an immune-derived moiety reactive against a bioactive lipid, wherein said immune-derived moiety is capable of decreasing the effective concentration of said bioactive lipid, thereby effecting treatment of said ocular disease or condition in said patient.
7 . A method according to claim 6 , wherein said immune-derived moiety is a monoclonal antibody or a fragment, variant, or a derivative thereof, optionally reactive against S1P or LPA or a variant thereof.
8 . A method according to claim 6 , wherein said bioactive lipid is a lysolipid, optionally S1P or LPA or a variant thereof.
9 . A method according to claim 6 , wherein said subject is a human subject.
10 . A method according to claim 6 , wherein said ocular disease or condition is characterized, at least in part, by aberrant fibrogenesis, fibrosis, or scarring.
11 . A method according to claim 10 , wherein said ocular disease or condition characterized, at least in part, by aberrant fibrogenesis, fibrosis or scarring is selected from the group consisting of age-related macular degeneration, diabetic retinopathy, retinopathy of prematurity, sickle cell retinopathy, ischemic retinopathies, retinal venous occlusive disease, macular pucker, cellophane retinopathy, ERM formation, contact lens overwear, tractional retinal detachment, proliferative vitreoretinopathy, traumatic injury, ocular cicatricial pemphigoid, Stevens Johnson Syndrome, toxic epidermal necrolysis, pterygium, and consequences of ocular surgery, including refractive surgery, vitrectomy and glaucoma surgery.
12 . A method according to claim 6 , wherein said ocular disease or condition is an inflammatory or immunologic condition.
13 . A method according to claim 12 , wherein said inflammatory or immunologic condition is selected from the group consisting of age-related macular degeneration, uveitis, vitritis, infections, including herpes simplex infection, herpes zoster infection and protozoan infection; corneal graft rejection and ocular histoplasmosis.
14 . A method according to claim 13 , wherein said age-related macular degeneration is dry age-related macular degeneration.
15 . A method according to claim 6 , wherein said ocular disease or condition is characterized, at least in part, by aberrant neovascularization.
16 . A method according to claim 15 , wherein said ocular disease or condition characterized, at least in part, by aberrant neovascularization is selected from the group consisting of age-related macular degeneration, diabetic retinopathy, retinopathy of prematurity, corneal graft rejection, neovascular glaucoma, contact lens overwear, infections of the cornea, including herpes simplex infection, herpes zoster infection and protozoan infection; pterygium, ischemic retinopathy, retinal venous occlusive disease, infectious uveitis, chronic retinal detachment, laser injury, sickle cell retinopathy, venous occlusive disease, choroidal neovascularization, retinal angiomatous proliferation, and idiopathic polypoidal choroidal vasculopathy.
17 . A method according to claim 6 , wherein said immune-derived moiety is administered systemically, topically, by intravitreal or periocular injection, iontophoresis, spray or drops, or as part of an in situ gel, ocular insert, corneal shield or contact lens, liposome, niosome/discome, mucoadhesive system, lyophilized carrier system, particulate, submicron emulsion, dendrimer, microsphere, nanosphere, or collasome, or combination thereof.
18 . A method according to claim 6 , wherein said immune-derived moiety is modified, unmodified, or provided as a prodrug, with or without enhancers and/or penetration enhancers.
19 . A pharmaceutical composition, comprising an immune-derived moiety reactive against a bioactive lipid and a pharmaceutically acceptable carrier.
20 . A pharmaceutical composition according to claim 19 that is suitable for use in and/or on an eye of a subject.